SPECIALTY QUANTITY LIMIT PROGRAM

COPIKTRA (duvelisib)

I. PROGRAM DESCRIPTION


The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Copiktra (duvelisib) 15 mg capsules	56 per 28 days	Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) OR Follicular
Copiktra (duvelisib) 25 mg capsules	56 per 28 days	lymphoma (FL): 25 mg twice daily Dose modification for toxicity or drug interactions: 15 mg twice daily

III. REFERENCES

1. Copiktra [package insert]. Needham, MA: Verastem, Inc.; September 2018.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2018 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of